IRVINE, Calif., Aug. 24 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. , today announced it will present at the following upcoming investor conferences:
Roth 2007 New York Conference
ISTA's Chief Financial Officer and Vice President of Corporate Development, Lauren Silvernail, will provide an update on the Company's commercial and clinical progress at 2:00 p.m. Eastern Time on Wednesday, September 5, 2007 at The Westin New York at Times Square.
Thomas Weisel Partners Healthcare Conference
ISTA's President and Chief Executive Officer, Vicente Anido, Jr., Ph.D. will provide an update on the Company's commercial and clinical progress at 9:45 a.m. Eastern Time on Thursday, September 6, 2007 at the Four Seasons Boston.
To access the live audio broadcasts or the subsequent archived recordings, log onto http://www.istavision.com. Please connect to the website several minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary.
About ISTA
ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. ISTA's products and product candidates addressing the $3.2 billion U.S. prescription ophthalmic industry include therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. The Company currently markets three products and is developing a strong product pipeline to fuel future growth and market share. The Company's product development and commercialization strategy is to launch a new product every 12 to 18 months, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website at http://www.istavision.com.
ISTA PharmaceuticalsCONTACT: Vince Anido, +1-949-788-5311, vanido@istavision.com; LaurenSilvernail, +1-949-788-5302, lsilvernail@istavision.com, both of ISTAPharmaceuticals; or Justin Jackson (Media), Burns McClellan,jjackson@burnsmc.com; Juliane Snowden (Investors), Burns McClellan,+1-212-213-0006, jsnowden@burnsmc.com, both for ISTA Pharmaceuticals
Web site: http://www.istavision.com/
